Tourmaline Bio Change in Accounts Payable 2020-2025 | TRML

Tourmaline Bio change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Tourmaline Bio Change in Accounts Payable 2020-2025 | TRML

Tourmaline Bio change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.3B
Zoetis (ZTS)$67.7B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$46.1B
BeOne Medicines - (ONC)$31.9B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$21.3B
Merck (MKKGY)$17.2B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.7B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11.7B
IPSEN (IPSEY)$10.9B
Stevanato Group S.p.A (STVN)$8B
Corcept Therapeutics (CORT)$7.2B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.7B
Madrigal Pharmaceuticals (MDGL)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B